These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16304159)

  • 1. Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.
    Zhu W; Burnette A; Dorjsuren D; Roberts PE; Huleihel M; Shoemaker RH; Marquez VE; Agbaria R; Sei S
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4965-73. PubMed ID: 16304159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
    Medveczky MM; Horvath E; Lund T; Medveczky PG
    AIDS; 1997 Sep; 11(11):1327-32. PubMed ID: 9302441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells.
    Zalah L; Huleihel M; Manor E; Konson A; Ford H; Marquez VE; Johns DG; Agbaria R
    Antiviral Res; 2002 Jul; 55(1):63-75. PubMed ID: 12076752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The history of N-methanocarbathymidine: the investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent.
    Marquez VE; Hughes SH; Sei S; Agbaria R
    Antiviral Res; 2006 Sep; 71(2-3):268-75. PubMed ID: 16730077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.
    Chen J; Dai L; Goldstein A; Zhang H; Tang W; Forrest JC; Post SR; Chen X; Qin Z
    PLoS Pathog; 2019 Dec; 15(12):e1008156. PubMed ID: 31790497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycolysis, Glutaminolysis, and Fatty Acid Synthesis Are Required for Distinct Stages of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
    Sanchez EL; Pulliam TH; Dimaio TA; Thalhofer AB; Delgado T; Lagunoff M
    J Virol; 2017 May; 91(10):. PubMed ID: 28275189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and metabolic activation of N-methanocarbathymidine, a novel thymidine analogue with a pseudosugar rigidly fixed in the northern conformation, in murine colon cancer cells expressing herpes simplex thymidine kinase.
    Noy R; Ben-Zvi Z; Manor E; Candotti F; Morris JC; Ford H; Marquez VE; Johns DG; Agbaria R
    Mol Cancer Ther; 2002 Jun; 1(8):585-93. PubMed ID: 12479218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.
    Kedes DH; Ganem D
    J Clin Invest; 1997 May; 99(9):2082-6. PubMed ID: 9151779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed inhibits Kaposi's sarcoma-associated herpesvirus replication through blocking dTMP synthesis.
    Chen J; Zhang H; Chen X
    Antiviral Res; 2020 Aug; 180():104825. PubMed ID: 32461120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells.
    Schelling P; Claus MT; Johner R; Marquez VE; Schulz GE; Scapozza L
    J Biol Chem; 2004 Jul; 279(31):32832-8. PubMed ID: 15163659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis.
    Dorjsuren D; Burnette A; Gray GN; Chen X; Zhu W; Roberts PE; Currens MJ; Shoemaker RH; Ricciardi RP; Sei S
    Antiviral Res; 2006 Jan; 69(1):9-23. PubMed ID: 16337284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An endothelial cell line infected by Kaposi's sarcoma-associated herpes virus (KSHV) allows the investigation of Kaposi's sarcoma and the validation of novel viral inhibitors in vitro and in vivo.
    Dubich T; Lieske A; Santag S; Beauclair G; Rückert J; Herrmann J; Gorges J; Büsche G; Kazmaier U; Hauser H; Stadler M; Schulz TF; Wirth D
    J Mol Med (Berl); 2019 Mar; 97(3):311-324. PubMed ID: 30610257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase.
    Cheng F; He M; Jung JU; Lu C; Gao SJ
    J Virol; 2016 Jul; 90(14):6515-6525. PubMed ID: 27147746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.
    Xu B; Wang L; González-Molleda L; Wang Y; Xu J; Yuan Y
    Antimicrob Agents Chemother; 2014; 58(1):563-73. PubMed ID: 24295975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine inhibits lytic replication of Kaposi's sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation.
    Yang M; Huang L; Li X; Kuang E
    Antiviral Res; 2016 Sep; 133():223-33. PubMed ID: 27521848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
    Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV pandemic response box.
    Okpara MO; Weaver F; Whitehouse A; Veale CGL; Edkins AL
    Antiviral Res; 2024 Oct; 230():105990. PubMed ID: 39154751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication.
    Uppal T; Meyer D; Agarwal A; Verma SC
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.